Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

The Leukemia & Lymphoma Society Available to Comment on FDA Approval of Seattle Genetics’ Adcetris, First New Treatment for Hodgkin Lymphoma Since 1977

August 19, 2011 By Bio-Medicine.Org

WHITE PLAINS, N.Y., Aug. 19, 2011 /PRNewswire/ — Today the Food
and Drug Administration (FDA) approved Seattle Genetics’ Adcetris
to treat two types of rare blood cancers – Hodgkin lymphoma
and anaplastic large cell lymphoma (ALCL).

(Logo:
http://photos.prnewswire.com/prnh/20110215/NY48642LOGO)

The drug is approved for Hodgkin lymphoma patients after failure
of a stem cell transplant or two chemotherapy treatments and for
ALCL patients after failure of at least one multi-agent
chemotherapy treatment.

“This is a great advance for patients battling both of these
diseases,” said Hildy Dillon, Senior Vice President of Patient
Services for The Leukemia & Lymphoma Society. “These are both
considered very curable diseases but there is a population of
patients from both diseases for whom treatment has not been
effective.”

Hodgkin lymphoma has an 86 percent survival and ALCL has an 80
percent cure rate.

“But for those people who don’t respond well these can be very
difficult cancers to cure. This advance gives new hope to that
group of patients,” Dillon said.

Dillon added that Seattle Genetics should be commended for
investing in a therapy for a very small subgroup of patients who
don’t respond to standard therapy and for whom there were very
limited options until now.

There are nearly 9,000 new cases of Hodgkin lymphoma diagnosed
each year and 3,000 new cases of ALCL, and both diseases primarily
impact children in their late teens and young adults.
 Adcetris is a targeted therapy linking a tumor-targeting
antibody to a chemotherapy drug with the goal of limiting side
effects.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society® (LLS) is the
world’s largest voluntary health agency dedicated to blood cancer.
The LLS mission: Cure leukemia, lymphoma, Hodgkin’s disease and
myeloma, and improve the quality of life of patients and their
families.

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech